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ABSTRACT 
Metabolic acidosis, indicated by low serum bicarbonate levels (CO2), is common 
in patients with end stage renal disease (ESRD). The specific aim of this project is to 
statistically correlate laboratory and descriptive human data with the association of 
serum CO2, metabolic acidosis, and nutritional assessment indices in hemodialysis 
patients. In a retrospective observational design, 144 hemodialysis patient charts were 
reviewed. One year of data was collected. To control for differences within individuals, 
within-subject correlations and analysis of covariance (ANCOVA) was used to analyze 
variables. Pearson and Spearman correlations were used to analyze correlations across 
the sample. Serum CO2 significantly correlated with albumin as an individual variable 
collected in the same month within-subjects (r = 0.079, p = 0.005), however not from the 
prior month (r = 0.042, p = 0.140). When including additional nutrition and inflammation 
related biomarkers (creatinine, hemoglobin, nPCR) with albumin and CO2 in an 
ANCOVA mixed model, within-subject correlation strengthened and was significant (r = 
0.093, p = 0.004) for the prior month’s CO2 impact on albumin. Albumin and the same 
month’s CO2 changed to not significant (r = 0.026, p = 0.412) in the mixed model. 
Despite small correlations with some variables, this study provides insight into why 
albumin does not always correlate with CO2 in hemodialysis patients. Results portray the 
benefit of correcting metabolic acidosis and the limitation of albumin as the main nutrition 
indicator and outcome goal in ESRD. Future research should focus on validating better 
nutritional outcome measures for patients with ESRD.  
 
KEY WORDS: End Stage Renal Disease (ESRD), Hemodialysis, Albumin, Bicarbonate, 
Malnutrition, Nutrition Indicators in ESRD, Nutritional Assessment 
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CHAPTER 1 
INTRODUCTION 
Low serum bicarbonate levels are common in individuals with chronic kidney 
disease (CKD) (1). According to the National Kidney Foundation’s Kidney Disease 
Outcome Quality Indicators (K/DOQI), serum bicarbonate levels should be measured 
monthly and maintained > 22 mEq/L. Levels < 22 mEq/L indicate metabolic acidosis (2). 
Metabolic acidosis in End Stage Renal Disease (ESRD) is the result of the kidney’s 
inability to synthesize ammonia from protein and excrete hydrogen ions (3). Concern 
arises when patients with ESRD are not able to maintain acid-base balance due to loss 
of kidney function. Negative nutrition outcomes including renal osteodystrophy, protein 
catabolism, decreased normalized protein catabolic rate (nPCR), decreased serum 
albumin synthesis, and protein energy wasting are observed with metabolic acidosis 
during maintenance hemodialysis (3, 4). Maintenance hemodialysis refers to the process 
of cleaning water and waste from blood using an artificial kidney or hemodialyzer. 
Maintenance hemodialysis can be done at a clinic, referred to as in-center dialysis (5).  
For the purpose of this thesis, the term dialysis refers to in-center maintenance 
hemodialysis.  
There is no one indicator providing a comprehensive assessment of nutritional 
status in ESRD (6, 7). Serum albumin is the main nutrition indicator and outcome used in 
assessment of ESRD and a measure of the visceral protein pool. The outcome goal for 
albumin according to K/DOQI is set at > 4.0 g/dL. Albumin values < 4.0 g/dL are 
associated with increased mortality in ESRD on dialysis (6, 8). One disadvantage of 
using serum albumin is it’s long half-life of ~ 20 days.  
Correcting low serum bicarbonate shows improved serum albumin levels in this 
patient population (9). It is hypothesized a low serum bicarbonate, indicating metabolic 
	  
	  
	  
2 
acidosis, influences albumin and other nutritional assessment indicies in hemodialysis 
patients. Nutrition assessment indicies include any of the monthly laboratories, 
subjective nutrition status designation, or anthropometrics. With serum albumin’s long 
half-life of 20 days, the prior month’s serum bicarbonate level (from ~ 20 days ago) 
would likely impact current serum albumin greater than current serum bicarbonate. The 
specific aim of this project was to statistically correlate laboratory and descriptive human 
data from in-center hemodialysis patients at Renal Advantage Incorporated in Westwood, 
KS.  
 
Purpose:  
The purpose of this thesis is to:  
1) Determine if serum bicarbonate influences albumin and nutrition assessment 
indices in hemodialysis patients. Nutrition assessment indicies include any of the 
monthly laboratories, subjective nutrition status designation, or anthropometrics. 
2) Demonstrate the prior month’s serum bicarbonate level has a greater impact on 
current serum albumin versus the current month’s serum bicarbonate in 
hemodialysis patients. 
 
Research questions: 
1. Are low bicarbonate levels (CO2) associated with low albumin and nutritional 
assessment indices in hemodialysis patients? Nutrition assessment indices 
include any of the monthly laboratories, subjective nutrition status designation, or 
anthropometrics. 
2. Is the preceding month’s serum CO2 (from ~ 20 days ago) associated with 
current serum albumin levels more than current serum bicarbonate levels?  
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CHAPTER 2 
LITERATURE REVIEW 
Chronic kidney disease stages 
The prevalence of ESRD is rising in the United States. The rate of ESRD cases 
was 1,763 per million in 2010, a four percent increase from 2009. At the end of 2010, 
there were 594,374 prevalent hemodialysis patients (10). Chronic kidney disease (CKD) 
is based on the presence of kidney damage and specific a glomerular filtration rate 
(GFR). Kidney damage is defined as pathological abnormalities or markers of damage 
with abnormalities in blood, urine, or imaging studies. Chronic kidney disease is defined 
as a GFR < 60 mL/min/1.73 m2 for > three months. The stages of CKD range from one 
to five and are outlined in Table 1. 
 
 
 
 
 
 
 
 
 
 
Kidney disease has numerous etiologies. Management and evaluation is based 
on the type of kidney disease. Clinical presentations and causal factors specify the type 
and origin of CKD. Final diagnosis is based on biopsy or imaging studies. The most 
frequent cause of kidney disease is diabetes mellitus. Poorly controlled type one and 
type two diabetes can result in CKD, with type two as the higher frequency. Diabetic 
TABLE 1. 
Stages of Chronic Kidney Disease (11) 
 
Stage Definition 
1 Normal GFR of > 90 mL/min/1.73 m2 but notable kidney damage 
2 Mild decrease in GFR of 60-89 mL/min/1.73 m2 
3 Moderately decreased GFR of 30-59 mL/min/1.73 m2 
4 Severely decreased GFR with a level of 15-29 mL/min/1.73 m2 
5 End stage renal disease, indicates kidney failure, a GFR of <15 
mL/min/1.73 m2, and need for dialysis 
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kidney disease often begins first with the onset of diabetes, followed by 
microalbuminuria, then proteinuria, hypertension, and finally decreasing GFR (11).  
Other glomerular diseases, vascular diseases, tubulointerstitial diseases, and 
cystic diseases, are often grouped as “nondiabetic kidney diseases”. In this category, 
hypertension is the second most common cause of renal disease, and glomerular 
diseases the third most common cause of renal failure. The diseases in this group differ 
based on history, clinical presentation, risk for progression, and response to treatment. 
Biopsy or invasive imaging studies are needed to differentiate among the diseases (11).  
The fourth most common causes of kidney disease are those related to 
transplants. Causes for failed transplants include organ rejection, toxicity due to anti-
rejection medications such as Cyclosporine or Tacrolimus, recurrence of the original 
disease, which caused their native kidneys to fail, and transplant glomerulopathy. 
Definitive diagnosis in failed transplants is performed with biopsies (11).  
 
Acid-base balance 
End stage renal disease can result in low serum bicarbonate levels, indicating 
metabolic acidosis (1, 2, 12).  For the purpose of this paper, serum bicarbonate refers to 
CO2. Metabolic acidosis is shown to have negative effects on nutrition indices including 
negative nitrogen balance, increased protein degradation, increased essential amino 
acid oxidation, reduced serum albumin synthesis, loss of lean body mass, and muscle 
weakness. Correcting metabolic acidosis is associated with improving these negative 
effects (2, 3,13). 
Blood acid-base balance is maintained through the lungs, kidneys, and a system 
of buffers. The lungs regulate the partial pressure of carbon dioxide (PaCO2 or PCO2). A 
normal PCO2 is 35–45 mm Hg. The lungs also assist in the oxygenation of blood. Oxygen 
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in the arterial blood is present as PaO2, dissolved oxygen and oxygen bound to 
hemoglobin. The lungs respond the quickest to acid-base imbalances through exhaling 
carbon dioxide, the acid component of the carbonic acid/bicarbonate buffer system (14). 
The role of the renal system in acid-base balance is to maintain the concentration 
of bicarbonate (CO2) in the blood at about 24 mEq/L with a normal range of 22-30 mEq/L 
for normal kidney function (14). The goal for CO2 for those receiving hemodialysis is > 
22 mEq/L (2). The kidneys maintain acid-base balance through reabsorption of filtered 
bicarbonate by the enzyme carbonic anhydrase in the proximal tubule. The kidneys also 
maintain acid-base balance through acid production (H+) and excretion of ammonium in 
the urine (14). To further review the role of the kidneys and lungs in maintaining acid-
base balance, respiratory alkalosis, respiratory acidosis, metabolic alkalosis, and 
metabolic acidosis, is outlined in Table 2.  
 
 
 
 
 
 
 
 
 
 
 
 
 
TABLE 2. 
Acid-Base Diagnoses (14) 
 
Diagnosis Description 
Respiratory 
alkalosis 
• Elevated pH > 7.45 
• Low PCO2 < 35 mm Hg 
Respiratory 
acidosis 
• Low pH < 7.35 
• Elevated PCO2 > 45 mm Hg 
Metabolic 
alkalosis 
• Elevated pH > 7.45 
• Elevated serum CO2 of > 30 mEq/L 
Metabolic 
acidosis 
• Low pH of < 7.35 
• Low serum CO2 level of < 22 mEq/L 
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The kidney’s role in acid-base balance 
The kidney is the main organ of excretion of acid load and hydrogen ions (H+) (2, 
3). Sources of acid production include loss of bicarbonate from the lower intestine, 
breakdown of proteins from diet, and oxidation of carbohydrates and fats in muscle cells 
(13, 15). The kidney assists in regenerating bicarbonate used for buffering acids and is 
vital in acid-base balance. Hydrogen ion concentration in the body is 40 nEq/L and 
equals a pH of 7.398, and normal acid base status. The use of pH may be misleading for 
the diagnosis of acidemia since pH does not clearly correlate to H+ concentration 
changes.  A blood pH of 7.30 would equal a H+ concentration of 50 nEq/L and a 
diagnosis of acidemia. A pH of 7.10 indicates severe acidemia, but the H+ concentration 
equals 80 nEq/L and double the normal H+ concentration (13). Although the use of 
blood pH is useful in determining acidosis, standard clinical practice in outpatient dialysis 
uses CO2 as an estimate of serum bicarbonate since dialysis clinics often do not have 
access to blood gas measurement instruments (1). Blood gas instruments use the 
Henderson-Hasselbalch equation to calculate CO2. The Henderson-Hasselbalch 
equation measures the partial pressure of CO2 (PCO2) (representing lung function) and 
bicarbonate (HCO3-) (representing kidney function): 
[H+] = 24 x PCO2/ [HCO3-] (13) 
The laboratory RenaLab used chemistry analyzers. Chemistry analyzers have 
blood gas instruments that convert HCO3- into CO2 and measure the (“total” CO2 = 0.03 
x PCO2) in samples. These levels are sometimes 1-2 mEq/L higher than true serum 
bicarbonate levels (13). Most of the CO2 is in the form of HCO3- in the body. Therefore, 
the CO2 blood test is a measure of blood bicarbonate level and the nonrespiratory or 
metabolic component of acid-base balance (16).  
A review by Chui et al. agrees routine measurement of arterial pH is often not 
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feasible or common in clinical practice. A high-normal arterial pH is generally associated 
with a CO2 level of 24–30 mEq/L when using the Henderson-Hasselbalch equation. The 
authors recommend this range as the therapeutic goal for chronic kidney disease 
patients with protein-energy wasting (17). 
 
Impact of metabolic acidosis in ESRD 
According to the National Kidney Foundation’s Kidney Disease Outcome Quality 
Indicators (K/DOQI), CO2 levels should be measured monthly and maintained > 22 
mEq/L. Levels < 22 mEq/L indicate metabolic acidosis (2). Metabolic acidosis in ESRD is 
the result of the kidney’s inability to synthesize ammonia and excrete hydrogen ions (3). 
Concern arises due to the inability of the kidney to excrete the hydrogen ions. Negative 
nutrition outcomes including renal osteodystrophy, protein catabolism, decreased 
normalized protein catabolic rate (nPCR), decreased albumin synthesis, and protein 
energy wasting are observed with metabolic acidosis in maintenance hemodialysis (3, 4). 
In a retrospective observational study in 2011 by Raphael et al., African 
Americans with higher and more normal CO2 levels of 28-30 mEq/L were associated with 
a lower risk of mortality. Low CO2 was an independent predictor of chronic kidney 
disease progression in this study (18). Soleymanian et al. found patients with metabolic 
acidosis to have a lower albumin even with adequate hemodialysis. An inverse effect of 
nPCR on albumin was found in acidotic patients. The authors believe metabolic acidosis 
leads to hypercatabolism and contributes to negative effects on nutritional status (19). 
Mortality is linked to metabolic acidosis with higher CO2 considered better for 
long-term patient outcomes (18). Wu et al. found the lowest unadjusted mortality to be 
associated with predialysis CO2 below 17-23 mEq/L. Bicarbonate values > 23 mEq/L 
were associated with higher total and cardiovascular death rates. After adjusting for 
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patient characteristics and malnutrition-inflammation complex syndrome multivariate 
adjustment, patients with bicarbonate values > 22 mEq/L had lower death risk (20). The 
international observational Dialysis Outcomes and Practice Patterns Study (DOPPS) 
found CO2 concentration to have no association between mortality at baseline or six-
months (21).  
A review by Gennari suggests attention should focus on patients with very low (< 
18 mEq/L), and very high CO2 levels (> 27 mEq/L). Gennari’s review found the lowest 
mortality risk in patients with levels of 18-23 mEq/L. Ensuring correct alkali delivery 
during hemodialysis therapy, evaluating potential acid–base disorders, and assessing 
diet and fluid retention between treatments is recommended for patients with low 
bicarbonate levels (22). 
 
Role of hemodialysis in correcting metabolic acidosis 
Hemodialysis assists in correcting metabolic acidosis and compensates for the 
kidney in ESRD. Dialysate fluids with added sodium bicarbonate are infused during the 
hemodialysis treatment. The concentration of bicarbonate dialysate can range from 30-
40 mmol/L for in-center hemodialysis (2, 23, 24). The mmol/L of bicarbonate dialysate 
prescribed is adjusted and based on a patient’s CO2 level. Oral pill supplementation is an 
option with the recommendation usually of 2-4 g/day or 25 to 50 mEq/day (2). Patients 
discussed in this study are all in-center hemodialysis patients who receive dialysate 
fluids with added bicarbonate during their dialysis treatment on average three days per 
week.  
 
Positive and negative results in correcting metabolic acidosis 
Studies indicate correcting acid-base imbalances have a positive effect on 
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preventing muscle wasting, low albumin, and decreased nutrition status. In acidosis, 
there is loss of protein from skeletal muscle. The protein loss results from accelerated 
breakdown of the myofibril proteins actin and myosin. The adenosine triphosphate 
(ATP)-dependent ubiquitin-proteasome system is increased and possibly responsible for 
accelerated proteolysis in metabolic acidosis (13, 25). A Cochrane review on the 
correction of metabolic acidosis found few randomized control trials demonstrate positive 
effects on nutrition when correcting metabolic acidosis in patients with kidney disease. 
Some studies in the Cochrane review demonstrated positive results while others did not 
(3).  
Lin et al. attempted to distinguish between metabolic acidosis due to poor 
nutrition versus metabolic acidosis due to better nutrient intake causing greater 
hydrogen production. They found patients with metabolic acidosis had a higher protein 
intake, higher nPCR, and were associated with better nutritional parameters. The 
authors suggest metabolic acidosis was not found to be a negative risk factor due to 
reflecting a higher protein intake, which is the precursor of hydrogen production (26). 
De Brito-Ashurst et al. found bicarbonate supplementation to slow the rate of 
progression of renal failure to ESRD and improve nutrition status in chronic kidney 
disease (CKD) patients (27). Blair and colleagues conducted an observational study and 
found increasing dialysate bicarbonate improved predialysis CO2 levels, decreased 
protein catabolism as measured by nPCR, and enhanced phosphorus control, but found 
no positive change in albumin (28). 
Ruggieria et al. conducted an intervention on eight hemodialysis patients. 
Patients were treated daily with oral sodium bicarbonate for 10–14 days. Despite 
improved acid-base balance of the patients, increasing patients to a more alkalotic state 
was not associated with a positive effect on albumin, muscle protein synthesis, or 
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nutritional and endocrinal parameters (29). Full benefits of the oral sodium bicarbonate 
could not have been seen in albumin due to albumin’s long half-life of about 20 days. In 
contrast, a six month study by Verove et al. found significant increases in both albumin 
and prealbumin levels using oral sodium bicarbonate (30). Movilli et al. in 2009 found no 
adverse effects in high interdialytic weight gains, plasma sodium, or blood pressure 
using oral sodium bicarbonate supplementation to correct metabolic acidosis in 
hemodialysis patients. Correcting metabolic acidosis was effective in reducing protein 
catabolism as defined by nPCR in hemodialysis patients. Albumin was only improved in 
patients without inflammation (31). One contributing factor for the varied results between 
metabolic acidosis and albumin could be the long half-life of albumin. 
 
Serum albumin as a nutrition indicator in ESRD 
There is no single protein-energy nutrition indicator for ESRD patients. The 
International Society of Renal Nutrition and Metabolism recommends the use of the term 
protein-energy wasting for loss of body protein mass and energy stores in chronic kidney 
disease and ESRD. To diagnose protein-energy wasting, three characteristics are 
present. The first includes low serum levels of albumin, prealbumin, or cholesterol. All 
three biomarkers have been used in the CKD population as nutritional biomarkers. The 
second characteristic includes reduced body mass as low or reduced body or fat mass 
or weight loss with reduced intake of protein and energy. Reduced muscle mass with 
muscle wasting, sarcopenia, or reduced mid-arm muscle circumference is the third 
recommended characteristic to diagnose protein energy wasting (32). In the United 
States, albumin continues to primarily be used as the main nutrition indicator and 
outcome goal for ESRD (8).  
Albumin is synthesized in the liver and has a long half-life of ~ 20 days (6, 33, 34). 
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It functions in maintaining osmotic pressure and transporting a variety of molecules 
throughout the body (7). Visceral protein pool size can be estimated by the 
measurement of circulating proteins in the blood, such as serum albumin (6, 34). Levels 
are influenced by exchanges between intra- and extracellular fluid compartments, 
lymphatic uptake, alterations in fluid status, protein degradation, body losses (i.e. 
proteinuria), inflammation, acid-base imbalance, the liver’s production of albumin, and 
acute phase response (4, 6-8, 33, 34). Debate continues regarding use of serum 
albumin as a nutrition indicator since a low level does not always indicate protein-energy 
malnutrition (6, 33). Although albumin levels of  < 4.0 g/dL are associated in ESRD with 
higher mortality rates, Friedman and Fadem suggest albumin should be used more as 
an index of the severity of illness versus nutrition status (7). Steinman suggests 
eliminating albumin totally as the nutrition indicator for ESRD (6). 
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CHAPTER 3 
MATERIALS AND METHODS  
Approval for the study was initially received from The University of Kansas 
Medical Center Human Subjects Committee. Renal Advantage, Incorporated (RAI) 
Medical Advisory Committee and RAI’s Chief Legal Counsel determined final approval. 
A limited data set was created with the assistance of RAI by removing protected health 
information as required by the Health Insurance Portability and Accountability Act 
(HIPAA). Kirk Finchem, RAI Vice President of Clinical Operations, assisted in creating 
the limited data set. All data was kept in a password protected and locked computer in a 
secure location at all times. 
 
Study design 
This study was a retrospective observational study using a convenience sample 
of 144 patients being treated with hemodialysis at RAI in Westwood, Kansas. Greater 
than one year’s data was collected to account for demonstrating the prior month’s serum 
bicarbonate level has an impact on nutrition indicators. Laboratory and medical histories 
were collected from electronic medical records from December 2010 through January 
2012. The electronic medical records were kept and backed up at RAI headquarters in 
Nashville, Tennessee. Patients were predominately on Medicaid and Medicare and of a 
lower socioeconomic status.  
 
Inclusion and exclusion criteria 
Subjects were included in data analysis regardless of comorbidities. Subjects 
were excluded for: 1) being on hemodialysis at RAI as defined as less than three 
months; 2) receiving artificial intravenous nutrition containing amino acids, such as total 
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parenteral nutrition (TPN) or intradialylitic parenteral nutrition (IDPN).  
 
Serum chemistry methods 
Certified Hemodialysis Technicians or Registered Nurses collected arterial blood 
samples at the beginning of each week on a Monday or a Tuesday based on a patient’s 
dialysis schedule. The blood tests listed below were collected monthly at the dialysis 
center according to the doctor’s orders (35). Blood samples were collected through the 
patients’ dialysis accesses (e.g. AV fistula, graft, or catheter). If a sample was 
hemolyzed, the clinic was notified and the samples were recollected. RenaLab, RAI’s 
laboratory located in Richland, Mississippi, analyzed the blood samples. RenaLab is no 
longer in business as of summer 2012 due Renal Advantage Inc. being purchased by 
another dialysis company. Details regarding laboratory assays and instruments are 
limited to what was available in the policies and procedures outlined below.  
Blood samples were air shipped overnight to RenaLab, Inc. for processing. Cold 
packs were first placed in the bottom of a RenaLab Transport Box on top of an 
absorbent blue pad. Samples were placed in holes of a foam insert in the shipping box. 
They were then packed in sealed plastic bags to prevent any broken or punctured tubes 
leaking into the box. Cold packs were placed on top to maintain preservation. A 
Styrofoam lid was placed on top of the contents. An itemized list of contents was placed 
between the Styrofoam lid and the outer box. The box was sealed with packing tape, 
labeled with a packing slip, and sent to RenaLab. Samples resulted in the patient 
electronic medical record after two days from shipment to RenaLab due to travel time 
(36).  
Patients’ body temperatures were recorded to assist in tracking potential illness 
or infection. Post dialysis weight (kg) was used to estimate dry weight after each 
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hemodialysis treatment. The dry weights recorded in the limited data set were from the 
same days as monthly lab days. Height (cm) was updated at least annually (37, 38). The 
dry weights and heights were used to calculate BMI as kg/m2 on the same day as 
monthly lab day. 
Subjective nutrition assessment data was collected from the comprehensive 
patient assessments with the classifications of “well nourished”, “mild malnutrition”, 
“moderate malnutrition”, and “severe malnutrition” (Appendix A). The nutrition status 
classification is based on criteria adopted from the Center for Disease Control’s ICD-9 
codes (39) and the Academy of Nutrition and Dietetics (AND) and American Society for 
Parenteral and Enteral Nutrition (A.S.P.E.N.) recommendations for malnutrition (40). 
Appendix B outlines the Nutrition Status Criteria table used in this study.  
A total of four blood tubes were collected with monthly labs including one serum 
separator tube (SST), two lavender topped tubes, and one green topped tube. Patient 
monthly labs included the following: 
 
1) Serum albumin: Serum albumin is an acute-phase protein with a goal of > 4.0 
g/dL in ESRD (8). The normal non-ESRD range for albumin is 3.5-5.2 g/dL (41). 
Albumin was analyzed by RenaLab using the bromocresol green assay (BCG). 
The BCG assay is a colorimetric method for the measurement of the serum 
albumin concentration and is shown to be the preferred method for hemodialysis 
patients (41). Bromocresol green dye binds with albumin at a specific pH. For 
example, a pH of 4.2 has a specific colored complex measured 
spectrophotometrically at 628 nm. It is directly proportional to the albumin 
concentration in the sample (42).  
 Arterial blood was collected in a serum separator tube (SST) tube and 
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allowed to clot for about 15 minutes (41). Each SST tube contained clot activator 
and gel for serum separation (43). The sample was centrifuged for 20 minutes at 
3000 rotations per minute (rpm) (8, 41).  
 
2) Serum bicarbonate: Serum bicarbonate (CO2) levels are influenced by kidney 
and respiratory function. The goal for ESRD is > 22 mEq/L CO2 (2). The kidney is 
the primary organ responsible for maintaining normal bicarbonate levels. The 
procedure uses a blood gas instrument and the Henderson-Hasselbalch equation 
where the partial pressure of CO2 (PCO2) represents lung function and 
bicarbonate (HCO3-) represents kidney function: 
 
[H+] = 24 x PCO2/ [HCO3-] (13). 
 
 
Because CO2 content primarily reflects the concentration of bicarbonate, it 
is primarily a measure of the nonrespiratory or metabolic component of acid-base 
balance (16). Arterial blood was collected in an SST and allowed to clot for about 
15 minutes (41). Each SST tube contained clot activator and gel for serum 
separation (43). The sample was then centrifuged for 20 minutes at 3000 rpm 
(41).    
 
3) Serum calcium: Serum calcium is used to determine parathyroid function and 
calcium homeostasis. Hyperparathyroidism is the most common cause of 
elevated serum calcium values, which leads to bone disease in ESRD. 
Hypoalbuminemia is the most common cause of decreased calcium values since 
calcium is bound to serum albumin (41). Adjusted calcium was calculated when 
albumin levels are < 4.0 g/dL using the equation:  
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[0.8 x (4.0 – Measured Serum Albumin g/dL) + Serum Calcium mg/dL] (41, 44).  
 
 
The desired goal for adjusted calcium range is > 8.4 - < 10.2 mg/dL in 
ESRD. Measurement is performed using a colorimetric assay. Arterial blood was 
collected in an SST and allowed to clot for about 15 minutes (41). Each SST tube 
contained clot activator and gel for serum separation (43). The sample was then 
centrifuged for 20 minutes at 3000 rpm (41).    
 
4) Serum creatinine: Serum creatinine is a product in the breakdown of muscle 
creatine phosphate from energy exertion. It is produced at a constant rate based 
on muscle mass and is excreted from the body by the kidneys (41). Patients with 
little or no renal function receiving dialysis will have predialysis serum creatinine 
levels proportional to dietary protein intake and skeletal muscle mass:  
 
Predialysis Serum Creatinine = [(Intake of Foods Rich in Creatine and Creatinine 
+ Endogenous Creatinine Production) – (Urine Output + Removal During 
Hemodialysis + Degradation of Creatinine)] (45) 
 
 
Normal kidney function creatinine range is 0.7-1.3 mg/dL for males and 
0.5-0.9 mg/dL for females (41). Creatinine levels above these ranges indicate 
impairment of kidney function, but a level < 10 mg/dL can be a sign of protein 
energy malnutrition, inadequate intake, and muscle wasting (45). Measurement 
was performed using a kinetic colorimetric Jaffe assay (41, 46). Creatinine reacts 
with alkaline picrate forming a red color in the Jaffe assay. The intensity of the 
color is measured spectrophotometrically. Sodium lauryl sulphate is added to 
prevent protein influence. Acidifying the sample with 30% acetic acid prevents 
influence from non-specific chromogens in the samples. A second absorbance 
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reading is taken. To determine creatinine results, the second absorbance values 
are subtracted from the first set of values. Corrected absorbance values are then 
plotted on a calibration graph. The measurable range with this graph is from 0.2 
to 8.0 mg/dL. Plotting the corrected absorbance of the test provides the values of 
creatinine (47). 
Arterial blood was collected in an SST and allowed to clot for about 15 
minutes (41). Each SST tube contained clot activator and gel for serum 
separation (43). The sample was then centrifuged for 20 minutes at 3000 rpm 
(41).    
 
5) Hemoglobin: Hemoglobin is a protein used to determine the oxygen-carrying 
capacity of blood, to assess ESRD related anemia, and to assess patient 
response to erythropoietin therapy. The kidney produces the hormone 
erythropoietin, which signals red blood cell production. Patients with ESRD do 
not produce a sufficient amount of erythropoietin to make red blood cells, 
resulting in erythropoietin-deficient anemia (48). The goal range for hemoglobin 
is 9-11 g/dL per RAI protocol (49).  Measurement was performed using a 
colorimetric assay. Arterial blood was collected in the first lavender-topped tube 
and immediately mixed by gentle inversion to allow the anticoagulant to combine 
with the blood and prevent clotting (41). Each lavender top tube contained the 
spray dried additive potassium (K2) ethylene diamine tetraacetic acid (K2EDTA) 
to assist in clotting (50). 
 
6) Intact parathyroid hormone: Intact parathyroid hormone (PTH) is produced by 
the parathyroid gland. Disorders of the parathyroid glands can lead to 
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hypercalcemia or hypocalcemia due to a change in PTH secretion (51). Patients 
with CKD frequently develop secondary hyperplasia of the parathyroid glands 
causing high blood levels of PTH. The abnormality develops due to 
hypocalcemia common in the course of kidney disease. A deficiency of 1,25-
dihydroxycholecalciferol [1,25(OH)2D3] (active vitamin D) also affects the function 
of the parathyroid glands. A decrease in vitamin D receptors and calcium-sensing 
receptors in the parathyroid gland occurs resulting in resistance to the action of 
vitamin D and calcium (52). 
Measurement of PTH was performed using an electrochemiluminescent 
immunoassay. Intact parathyroid hormone was collected monthly after Zemplar ® 
vitamin D analogue medication adjustments or if PTH levels were considered 
unstable. An unstable PTH was defined as < 150 or > 300 pg/dL per RAI protocol 
(49). If PTH was stable after two months, it was tested quarterly. Arterial blood 
was collected in the second lavender-topped tube and immediately mixed by 
gentle inversion to allow the anticoagulant to combine with the blood and prevent 
clotting (51). Each lavender top tube contained the spray dried additive 
potassium (K2) ethylene diamine tetraacetic acid (K2EDTA) to assist in clotting 
(50).  
 
7) Serum phosphorus: There is an inverse relationship between serum 
phosphorus and serum calcium levels. Excess serum phosphorus levels cause 
the kidneys to excrete serum calcium. Excess serum calcium levels cause the 
kidneys to excrete serum phosphorus. The ESRD goal range for serum 
phosphorus is 3.5-5.5 mg/dL per RAI protocol (49). Measurement was performed 
using a colorimetric assay. Arterial blood was collected in an SST and allowed to 
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clot for about 15 minutes (51). Each SST tube contained clot activator and gel for 
serum separation (43). The sample was then centrifuged for 20 minutes at 3000 
rpm (51).    
 
8) Serum potassium: Serum potassium is the primary electrolyte of intracellular 
fluid. The goal range for potassium is 3.5-5.5 mEq/L per RAI protocol (49). 
Measurement was performed using an ion selective electrode for potassium. 
Arterial blood was collected in an SST and allowed to clot for about 15 minutes 
(51). Each SST tube contained clot activator and gel for serum separation (43). 
The sample was then centrifuged for 20 minutes at 3000 rpm (51).   
 
9) Kt/V, pre-blood urea nitrogen, and post-blood urea nitrogen: Hemodialysis 
adequacy, defined by Kt/V, is taken at least monthly using pre-treatment blood 
urea nitrogen (pre-BUN) and post-treatment BUN (mg/dL) (post-BUN). The letter 
K represents clearance of urea, t represents hemodialysis time, and V represents 
volume of distribution of urea (53). Blood urea nitrogen is used to evaluate kidney 
function. Urea is formed in the liver in the urea cycle and represents the final 
products of protein and amino acid metabolism. Urea is carried to the kidneys to 
be excreted in the urine (41). A normal BUN is 7-20 mg/dL (54). Protein 
catabolism and impairment of kidney function results in a high BUN above 20 
mg/dL (41). The Daugirdas II logarithmic kinetics Kt/V method is the tool used for 
measuring and assessing the effectiveness of hemodialysis (41, 55): 
 
Kt/V = -ln(Post BUN/Pre BUN-0.008·t) + (4–3.5·Post-BUN/Pre-BUN)·Ultrafiltrate 
Volume/Weight (56) 
 
 
Pre-BUN samples were collected arterially in an SST and allowed to clot for 
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about 15 minutes. The sample was then centrifuged for 20 minutes at 3000 rpm. 
Post-BUN samples were collected arterially in a green-topped tube. Green 
topped tubes are mixed by gentle inversion to allow the anticoagulant to combine 
with blood and prevent clotting. Green topped tubes required no centrifuging (41). 
Each green topped tube contained spray dried lithium heparin to prevent clotting 
(57). If Kt/V levels were less than the goal of 1.4, hemodialysis prescriptions were 
adjusted to achieve the goal of > 1.4.  
 
10) Normalized protein catabolic rate: Normalized protein catabolic rate (nPCR) 
is calculated with each Kt/V as an estimate of protein intake by g/kg/day. The 
ideal nPCR range is > 1.2, indicating an intake of about 1.2 g/kg/day of protein 
(53). There are limitations to nPCR as an estimate of protein intake. First, nPCR 
approximates protein intake only when the patient is in nitrogen equilibrium 
(steady-state). In a catabolic patient, nPCR will appear higher than protein intake 
from degradation and metabolism of protein pools to form urea. Second, a single 
measurement may not reflect usual protein intake. When protein intake is high, 
nPCR underestimates protein intake where nitrogen balance is positive. 
Normalized protein catabolic rate may overestimate protein when the protein 
intake is less than 1 g/kg/day, possibly due to protein catabolism (58).   
 
Statistical analysis 
Data was analyzed using Statistical Package for Social Sciences 20 (SPSS 20). 
Outliers in the limited data set for all variables were removed. An outlier was defined as 
a not feasibly possible value or lies outside the possible range of values for any given 
variable. The program SPSS automatically removed variables through pairwise deletion 
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for cases with missing values. Laboratory and anthropometric data analyzed included 
serum albumin, serum CO2, serum phosphorus, hemoglobin, adjusted serum calcium, 
serum potassium, PTH, Kt/V, pre- BUN, post-BUN, serum creatinine, nPCR, 
temperature during hemodialysis, weight, height, and BMI. Patient characteristics 
collected included gender, age, cause of renal failure, BMI class, months on 
hemodialysis, and subjective nutrition status. The variable of race/ethnic group was 
originally requested, however was excluded from analysis.  
To control for differences among individuals, within-subject correlations were 
used to analyze individual variables and the mixed model ANCOVA variables. For 
example, to determine if a decrease in albumin within an individual was associated with 
a decrease in CO2, the differences between subjects were removed and only changes 
within the individual was calculated (59). The following calculation was used to find 
within-subjects correlation:  
 
√(Sum of Squares for Variable of Interest)/(Sum of Squares for Variable of Interest + 
Sum of Squares Residual) (59) 
 
 
P-values of < 0.05 were considered to be statistically significant for all within-subjects 
correlations.  
 Pearson correlations were calculated to ensure reliability of the within-subjects 
correlation for continuous variables across subjects. Spearman correlations were 
calculated to ensure reliability of the within-subjects correlation for categorical variables 
across subjects. Pearson and Spearman calculations also assisted in determining the 
directionality (positive or negative) of the correlation as the within-subject correlation 
losses the negative directionality when calculating with a square root. P-values of < 0.05 
and < 0.01 were considered to be statistically significant depending on variable. 
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Chapter 4 
RESULTS 
Sample characteristics and descriptives 
 The sample included 144 in-center hemodialysis patients, 87 males and 57 
females. Patient characteristics are presented in Table 3. The mean age was 56.75 + 
15.21 years with a majority of patients between the ages of 40 and 69 years (68.7%).  
 Cause of renal failure was subcategorized according to the Department of Health 
and Human Services and Center for Medicare and Medicaid Services Form-CMS-U3: 
List of Primary Causes of ESRD (60). The primary causes of ESRD categories are listed 
in Table 3. The top two causes of ESRD were 28.5% caused by diabetes and 35.4% 
caused by hypertension/large vessel disease.  
 The mean BMI was 28.11 + 6.65 kg/m2. The majority of patients had a desirable 
weight (39.6%). Subcategories were based on the BMI criteria of the National Heart 
Lung and Blood Institute and National Institutes of Health (61) (Table 3).  
 Patients were excluded if they were new to hemodialysis as defined by less than 
three months of receiving treatment. The mean months on hemodialysis were 51.78 + 
45.80 months with a minimum of three months and a max of more than 23 years (287.10 
months) (Table 4).  
  Monthly laboratory values included albumin, bicarbonate, phosphorus, 
hemoglobin, adjusted calcium, potassium, PTH, Kt/V adequacy calculation derived from 
pre-BUN and post-BUN, creatinine, nPCR, and patient temperature during hemodialysis. 
Patient laboratory descriptives are shown in Table 4.  
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TABLE 3. 
Patient Characteristics (n = 144) 1, 2 
 
 Number Percent 
(100%) 3  
Gender   
Male 87 60 
Female 57 40 
Age (Years)   
20-29 8 5.6 
30-39 9 6.3 
40-49 30 20.8 
50-59 39 27.1 
60-69 30 20.8 
70-79 17 11.8 
80-89 10 6.9 
90-100 1 0.7 
Cause of Renal Failure 4   
Diabetes 41 28.5 
HTN/Large Vessel Disease 51 35.4 
Glomerulonephritis 14 9.7 
Secondary Glomerulonephritis/Vasculitis 4 2.8 
Interstitial Nephritis/Pyelonephritis 1 0.7 
Cystic/Hereditary/Congenital Diseases 2 1.4 
Neoplasms/Tumors 5 3.5 
AIDS Nephropathy 2 1.4 
Hepatorenal Syndrome 1 0.7 
Complications of Transplant 3 2.1 
Not specified/Other Diagnosis 20 13.9 
BMI 5   
Underweight 6 4.2 
 Desirable Weight 57 39.6 
Overweight 44 30.6 
Obese Class I 20 13.9 
Obese Class II 8 5.6 
Obese Class III 8 5.6 
1 Does not always add to total sample size due to missing values 
2 Race/ethnic group not included due to more than 50% missing data from the database 
3 Percents do not always add up to 100 due to rounding  
4 Subcategories based on Form CMS-2728-U3: List of Primary Causes of ESRD 
5 Subcategories based on National Heart Lung and Blood Institute and National Institutes of 
Health BMI criteria 
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Nutrition Assessment 
Dietary intake was not collected for this project due to time constraints. Nutrition 
status was determined at least annually on stable patients by a Registered Dietitian. 
Medically unstable patients were assessed more often until deemed stable. The 
Comprehensive Patient Nutrition Assessment included appetite, typical meal pattern, 
anthropometrics, and laboratory results (Appendix A) (62). Each Comprehensive Patient 
Nutrition Assessment provided a designation of whether a patient was “well-nourished”, 
or had a “mild”, “moderate”, or “severe malnutrition” status. Criteria for nutrition status 
were based on findings from the Comprehensive Patient Nutrition Assessment and 
Nutrition Status Criteria outlined in Appendix B. Table 5 shows the nutrition status of 
those patients who had nutrition assessments during the study time. The chi-squared 
test is used to test hypotheses relating to group differences in proportions (63). When 
evaluating the difference between the nutrition status designations, the groups were not 
statistically the same as designated by a Chi-squared of 50.44 (p = 1.11325E-11). 
TABLE 4. 
Patient Laboratory Descriptives (n = 144) 1 
 
Biomarker Mean Minimum  Maximum  
Standard 
Deviation  
Age (years) 56.75 21.10 90.50 15.21 
BMI (kg/m2) 28.11 15.60 53.50 6.65 
Months on Hemodialysis 51.78 3.00 287.10 45.80 
Albumin (g/dL) 3.75 1.90 5.00 0.40 
Bicarbonate (mEq/L) 23.95 12.00 35.00 3.24 
Phosphorus (mg/dL) 5.48 1.50 13.00 1.68 
Hemoglobin (g/L) 10.86 5.50 15.60 1.36 
Adjusted Calcium (mg/dL) 9.05 5.80 13.20 0.81 
Potassium (mEq/L) 4.63 2.50 8.10 0.73 
Intact PTH (pg/dL) 489.09 2.00 2272.00 396.10 
Kt/V 1.69 0.44 4.53 0.36 
Pre-BUN (mg/dL) 60.40 14.00 139.00 19.87 
Post-BUN (mg/dL) 17.55 2.00 80.00 9.71 
Creatinine (mg/dL) 9.71 2.13 22.29 3.46 
nPCR 0.89 0.17 2.29 0.32 
Temperature During Hemodialysis (°F) 97.17 93.90 101.40 1.01 
1 Each variable does not always include total sample size due to missing values.  
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Correlation of patient variables 
Pearson correlations designate the relationship or magnitude between two 
continuous variables measured on an interval scale. For example, the variable albumin 
is a continuous variable that was measured using Pearson correlation. Spearman 
correlations indicate the relationship or magnitude between two variables measured on 
an ordinal or categorical scale. The variable nutrition status is a categorical variable and 
was measured using Spearman correlation (63). Pearson and Spearman correlations 
determine relationships between subjects in the sample.  
The correlation between albumin and each of the patient variables are shown in 
Table 6. Notable within-subject positive correlations significant (p < 0.05) with albumin 
were biomarkers known to trend with nutrition and inflammation in this patient population 
including hemoglobin, pre-BUN, creatinine, and nPCR. Pearson or Spearman 
correlations significant with albumin were the nutrition status and biomarkers known to 
trend with nutrition and inflammation including hemoglobin and creatinine. Nutrition 
status had a strong Spearman correlation with albumin in the same month and even 
strengthened with the prior month’s nutrition status. This portrays the concept that due to 
albumin’s long half-life, a stronger correlation will be seen in the current albumin with the 
health and nutrition status of the patient about 20 days ago. All variables were significant 
at p < 0.01 except for temperature, which was significant at p < 0.05.  
TABLE 5. 
Patient Nutrition Status from Comprehensive Patient Assessment (n = 104) 1 
 
Nutrition Status 2 Number Percent 
Well Nourished 63 61 
Mild Malnutrition 37 35 
Moderate Malnutrition 4 4 
Severe Malnutrition 0 0 
1 Does not add up to total population due to patients who were not up for their annual 
review or those who had expired, transplanted, or transferred before their annual review 
2 Based on Appendix A and Appendix B criteria 
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 The correlation between bicarbonate and each of the patient variables are shown 
in Table 7. Notable within-subject correlations significant with bicarbonate (p < 0.05) 
were mineral-bone related biomarkers including phosphorus and adjusted calcium. 
Bicarbonate correlated with nutrition biomarkers including hemoglobin, pre-BUN, post-
BUN, creatinine, and nPCR. The Pearson or Spearman correlations assisted in 
assigning directionality to the within-subjects correlation. For example, phosphorus and 
the nutrition biomarkers BUN and nPCR negatively correlated with bicarbonate. A higher 
CO2 therefore indicated a lower phosphorus, BUN, and nPCR. All variables were 
significant at p < 0.01 except for BMI, which was significant at p < 0.05. The correlation 
between the prior month’s bicarbonate and the individual patient variables are shown in 
Table 8. Within-subject correlations, Pearson, and Spearman correlations did not 
improve with the prior month’s bicarbonate and the individual patient variables in Table 8. 
TABLE 6. 
Correlation of Patient Variables with Albumin (n = 144) 1 
 
Patient Variable 
Within-
Subjects 
Correlation P 
Pearson or 
Spearman 
Correlation 3  P  
Age (years) 0.009 0.000 2 -0.076 0.004 4 
BMI (kg/m2) 0.028 0.314 -0.029 0.272 
Months on Hemodialysis 0.009 0.756 -0.066 0.013 4 
Nutrition Status  0.098 0.618 -0.566 0.000 4 
Nutrition Status Prior Month 0.240 0.212 -0.631 0.000 4 
Bicarbonate Same Month (mEq/L) 0.079 0.005 2 0.024 0.376 
Bicarbonate Prior Month (mEq/L) 0.042 0.140 0.083 0.002 4 
Phosphorus (mg/L) 0.099 0.000 2 0.176 0.000 4 
Hemoglobin (g/L) 0.287 0.000 2 0.247 0.000 4 
Adjusted Calcium (mg/dL) 0.004 0.886 0.005 0.867 
Potassium (mEq/L) 0.108 0.000 2 0.131 0.000 4 
Intact PTH (pg/dL) 0.109 0.001 2 0.134 0.000 4 
Kt/V 0.099 0.001 2 0.207 0.000 4 
Pre-BUN (mg/dL) 0.125 0.000 2 0.088 0.001 4 
Post-BUN (mg/dL) 0.099 0.001 2 0.051 0.078 
Creatinine (mg/dL) 0.097 0.001 2 0.224 0.000 4 
nPCR 0.121 0.000 2 0.119 0.000 4 
Temperature During Treatment (°F) 0.493 0.086 -0.063 0.020 2 
1 Each variable does not always include total sample size due to missing values 
2 Correlation is significant at the 0.05 level  
3 Pearson values correlate continuous variables and Spearman values correlate categorical variables 
4 Correlation is significant at the 0.01 level 
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TABLE 8. 
Correlation of Prior Month Bicarbonate with Patient Variables (n = 144) 1 
 
Patient Variable 
Within-
Subjects 
Correlation P  
Pearson or 
Spearman 
Correlation 3  P  
Age (years) 0.052 0.063 0.007 0.799 
BMI (kg/m2) 0.037 0.194 0.075 0.005 4 
Months on Hemodialysis 0.052 0.066 0.115 0.000 4 
Nutrition Status  0.021 0.922 0.059 0.508 
Phosphorus (mg/L) 0.057 0.045 2 -0.160 0.000 4 
Hemoglobin (g/L) 0.007 0.800 0.044 0.103 
Adjusted Calcium (mg/dL) 0.026 0.364 0.081 0.003 4 
Potassium (mEq/L) 0.050 0.080 -0.066 0.014 2 
Intact PTH (pg/dL) 0.063 0.063 -0.092 0.004 4 
Kt/V 0.010 0.744 0.023 0.417 
Pre-BUN (mg/dL) 0.025 0.375 -0.129 0.000 4 
Post-BUN (mg/dL) 0.106 0.000 2 -0.104 0.000 4 
Creatinine (mg/dL) 0.012 0.633 0.052 0.056 
nPCR 0.145 0.000 2 -0.158 0.000 4 
Temperature During Treatment (°F) 0.046 0.113 -0.010 0.704 
1 Each variable does not always include total sample size due to missing values. 
2 Correlation is significant at the 0.05 level  
3 Pearson values correlate continuous variables and Spearman values correlate categorical variables 
4 Correlation is significant at 0.01 level 
 
 
 
TABLE 7. 
Correlation of Bicarbonate with Patient Variables (n = 144) 1 
 
Patient Variable 
Within-
Subjects 
Correlation P  
Pearson or 
Spearman 
Correlation 3 P 
Age (years) 0.064 0.022 2 0.004 0.890 
BMI (kg/m2) 0.018 0.520 0.053 0.046 2 
Months on Hemodialysis 0.064 0.023 2 0.117 0.000 4 
Nutrition Status  0.293 0.138 -0.042 0.643 
Phosphorus (mg/L) 0.260 0.000 2 -0.268 0.000 4 
Hemoglobin (g/L) 0.112 0.000 2 -0.038 0.160 
Adjusted Calcium (mg/dL) 0.212 0.000 2 0.194 0.000 4 
Potassium (mEq/L) 0.310 0.000 2 -0.230 0.000 4 
Intact PTH (pg/dL) 0.087 0.009 2 -0.117 0.000 4 
Kt/V 0.022 0.465 0.040 0.162 
Pre-BUN (mg/dL) 0.400 0.000 2 -0.327 0.000 4 
Post-BUN (mg/dL) 0.215 0.000 2 -0.169 0.000 4 
Creatinine (mg/dL) 0.266 0.000 2 -0.037 0.166 
nPCR 0.140 0.000 2 -0.175 0.000 4 
Temperature During Treatment (°F) 0.013 0.641 0.017 0.533 
1 Each variable does not always include total sample size due to missing values. 
2 Correlation is significant at the 0.05 level  
3 Pearson values correlate continuous variables and Spearman values correlate categorical variables 
4 Correlation is significant at the 0.01 level  
	  
	  
	  
28 
Mixed model ANCOVA 
 Analysis of covariance is a statistical procedure used to test mean differences 
among groups on a dependent variable, while controlling for or including one or more 
covariates (variables) (63). Table 9 shows a mixed model of including additional nutrition 
indicators with the albumin and bicarbonate analysis. Albumin significantly correlated 
with bicarbonate within-subjects in the same month when calculated alone in Table 6. 
Albumin was not significant with bicarbonate within-subjects from the prior month when 
calculated alone in Table 6. When including additional specific nutrition and inflammation 
related indicators, the within-subject correlation strengthened and was significant for the 
prior month’s bicarbonate impact on albumin. Albumin and the same month’s 
bicarbonate became not significant and had a lower correlation when adding covariates 
compared to Table 6. 
 
TABLE 9. 
Mixed Model ANCOVA (n = 144) 1 
 
Patient Variable 
Albumin and 
CO2 from the 
Same Month 2  P 3 
Albumin from 
Current Month 
and CO2 from 
Prior Month 2 P 3 
Hemoglobin (g/L) 0.284 0.000 0.292 0.000 
Creatinine (mg/dL) 0.142 0.000 0.151 0.000 
nPCR 0.068 0.031 0.085 0.008 
Bicarbonate (mEq/L) 0.026 0.412 0.093 0.004 
1 Each variable does not always include total sample size due to missing values. 
2 Within-subjects correlations 
3 Correlation is significant at the < 0.05 level 
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Chapter 5 
DISCUSSION 
Serum CO2 is the primary hemodialysis outpatient biomarker used to determine 
acid-base status of this patient population. Low serum bicarbonate is shown to 
negatively impact nutrition status and biomarkers such as albumin. Albumin is known to 
have a long half-life of ~20 days and not always indicate the current nutrition status of a 
patient. As an individual indicator, albumin did not correlate significantly with the prior 
month’s bicarbonate within-subjects (r = 0.042, p = 0.140), but did in the same month (r 
= 0.079, p = 0.005). When including additional nutrition indicators as outlined in the 
ANCOVA model, albumin did significantly correlate with bicarbonate from the prior 
month (r = 0.093, p = 0.004). Because there is no one biomarker indicating overall 
nutrition status in hemodialysis patients, it is important for clinicians to consider multiple 
biomarkers versus only albumin as the main nutrition indicator in ESRD.  
This study’s results support the potential reason some studies find significance 
for metabolic acidosis on nutrition biomarkers such as albumin while other research 
does not. Results appear to be the first to take both current and prior month’s serum CO2 
and correlate them to nutrition biomarkers in hemodialysis patients. A patient’s prior 
month’s CO2 was used to see if it correlated better with the biomarker albumin which is 
know to have a long half-life. A further advantage of this study was the use of both 
within-subjects and Pearson or Spearman correlations. Studies often appear to only use 
Pearson correlation to look at the relationship of CO2 and biomarkers between subjects 
(9, 19, 28) and not at trends within the individual.  
Intervention studies have attempted to answer the question whether increasing 
serum CO2 improves protein synthesis and albumin. Ruggieri et al. found raising blood 
pH of dialysis patients was not associated with a positive effect on albumin and muscle 
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protein synthesis, or nutritional and endocrinal parameters (29). Bossola et al. found no 
significant effect of bicarbonate treatment on albumin, dry weight, total cholesterol, or C-
reactive protein (64). Movilli et al. in 1998 demonstrated the correction of metabolic 
acidosis improved serum albumin concentrations in hemodialysis patients from 3.49 + 
2.1 g/dL to 3.79 + 2.9 g/dL (p < 0.01) (65). Movilli and colleagues in 2009 found 
correcting metabolic acidosis in hemodialysis patients increased albumin only in patients 
without inflammation (C-reactive protein < 10 mg/L) from 3.7 + 0.3 g/dL to 4.0 + 0.3 g/dL 
(p < 0.01). In inflamed patients, the correction of low CO2 did not improve albumin (3.5 + 
0.17 g/dL vs. 3.4 + 0.13 g/dL; p = NS) (31). This current study suggests when looking 
within individual patient trends (within-subjects correlation), a higher albumin significantly 
correlated with a higher CO2 collected in the same month (r = 0.079, p = 0.005). Albumin 
did not significantly correlate as hypothesized with CO2 collected from the prior month 
within-subjects. However, the correlation was significant between subjects (Pearson 
correlation) for albumin and prior month’s CO2.  
Normalized protein catabolic rate is used as a biomarker for trending estimated 
protein intake as defined by grams of protein consumed per kilogram body weight (53). 
This study showed a significant trend in a lower nPCR with a higher CO2. Blair et al. 
found similar results in nPCR after increasing bicarbonate dialysate from 35 to 39 
mmol/L for six months. The nPCR decreased significantly compared to baseline (0.99 + 
0.26 vs. 0.93 + 0.23, p = 0.001) (28). Results from Movilli et al. in 2009 were consistent 
with this study, but they supplemented ESRD patients with oral sodium bicarbonate. The 
nPCR decreased significantly (1.13 + 0.14 g/kg/day to 1.05 + 0.14 g/kg/day, p < 0.0001) 
(31). Lin et al. evaluated acidotic hemodialysis patients and the effect on nutritional 
status of increasing the bicarbonate dialysate from 35 to 38 mmol/L for one month and 
then to 38–40 mmol/L for five months. The nPCR was lower with those patients who had 
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a higher CO2 (p < 0.001). Lin et al. states, it appears a higher rate of endogenous protein 
production, and therefore nPCR, from protein oxidation contributes to the lower 
predialysis CO2 (26).  
Subjective Global Assessment (SGA) scores were not calculated for patients at 
RAI to determine nutrition status. Scores for SGA are based on a medical history and 
physical examination using a four-item, seven-point scale by Baker and colleagues. A 
higher score indicates better nutrition (66). Nutrition status for RAI patients are based on 
findings from the Comprehensive Patient Nutrition Assessment and malnutrition 
diagnosis criteria outlined in Appendix B. Albumin and nutrition status designation 
negatively trended between subjects’ results and had an even stronger correlation with 
the prior month’s nutrition status. A strong negative correlation was found because “well-
nourished” = 1, “mild” = 2, “moderate” = 3, and “severe malnutrition” = 4 on the patient 
nutrition assessment, indicating a higher albumin did trend with a better nutrition status 
of “1”. Nutrition status did not correlate with the same month’s CO2 or the prior month’s 
CO2 in this study. Szeto et al. in 2003 found overall improved SGA score when 
correcting CO2 in the treatment group compared the placebo group at 24 weeks (5.07 
points + 0.94 vs. 4.40 points + 1.00, p = 0.015). This study’s results are more consistent 
with Bossola et al. Bossolo and colleagues which showed no improved SGA after 12 
months (4.53 points + 0.37 at baseline and 4.58 points + 0.54 (p = 0.1).  
Analysis of covariance includes additional variables in the correlation, which 
could have an impact on the dependent variable. Additional nutrition related covariates 
such as hemoglobin, creatinine, nPCR, were analyzed with albumin and CO2 in a mixed 
model ANCOVA. Other variables were attempted in the mixed model including impact of 
age, gender, Pre-BUN, and nutrition status, however they were not significant (not 
shown). ANCOVA correlations were higher and all significant for the prior month’s CO2 
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and albumin compared to the same month’s CO2 and albumin. ANCOVA correlations 
were also all higher and significant compared to when albumin was analyzed alone with 
CO2. Including multiple nutrition or inflammatory variables versus only albumin improved 
the correlations with single variables in Table 6. Kovesdy et al. conducted a similar 
analysis combining three biomarkers albumin, percent lymphocytes, and white blood 
cells and their correlation on all-cause mortality in CKD patients. Lower serum albumin 
and percent lymphocytes and a higher WBC count, alone or in combination, were 
independently associated with increased all-cause mortality (67).  
The within-subjects correlations provided positive correlations and significance. 
The Pearson correlations assisted in detecting the lost negative correlation in the within-
subjects correlation. Phosphorus, potassium, and pre-BUN were negatively correlated 
with CO2. Results indicate a higher CO2 trends with lower or more normal phosphorus, 
potassium, and pre-BUN, which are consistent with findings by Wu et al. (20). The 
variables did not trend as high when analyzed with the prior month’s CO2. Phosphorus, 
potassium, and pre-BUN had lower correlations with the prior month’s CO2 and not all 
variables were significant. The correlation of bone related labs, such as phosphorus, 
with bicarbonate is consistent with the literature as metabolic acidosis worsens bone 
disease (15, 68). Due to the buffer function of bone, calcium and phosphate release from 
bone into blood stream (68). Potassium was inversely associated with bicarbonate. A 
higher CO2 was associated with lower potassium in this study. A higher CO2 was 
associated with a lower pre-BUN in this study. Pre-BUN was lowered by Ruggieri and 
colleagues after correcting metabolic acidosis (29). Correction of acidosis can reduce 
muscle protein degradation and reduce urea generation rates (23). Williams et al. found 
a slight initial lowered BUN after one month of administering a high 40 mmol/L 
bicarbonate bath. However they did not find continued lowered urea after 12 months (23). 
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Limitations 
Using serum CO2 to determine metabolic acidosis has the potential for 
inaccuracy if sample tubes are underfilled. Underfilled samples influence the dissipation 
of CO2 and may result in falsely low measurements (13). Renal Advantage Inc. 
employees who collect blood samples are educated on the correct method for collection 
and handling upon hire. The blood samples were not analyzed at a close location to the 
dialysis unit and were processed in Richmond, Mississippi by RenaLab. The mean total 
CO2 content of shipped blood samples can be up to ~5 mEq/L lower than samples 
processed immediately. Changes in atmospheric pressure in pressurized airliner cabins 
or in the cargo hold lead to the escape of CO2 from the tube. If the sample is stored at 
room temperature or refrigerated for 24 hours, without air transport, the change in total 
CO2 is only ~1 mEq/L (2, 13). 
Certain labs are only collected on a monthly basis, such as CO2 and albumin. 
One monthly result does not fully determine health trends throughout the rest of the 
month on patients. A nutrition assessment was conducted for most patients one time per 
year, which does not reflect the nutrition status of the patient throughout the rest of the 
year. Race/ethnic group was excluded due a significant amount of missing 
demographics. This was due to the newness of the electronic medical record system for 
the time the limited data set was collected.  
This study was limited by its observational design and establishes associations. 
The sample was from a single clinic and therefore may not generalize to the entire 
ESRD population. It would be beneficial for future researchers to both provide 
intervention of correcting metabolic acidosis and assess the impact the prior month’s 
bicarbonate on nutrition biomarkers and nutrition status.  
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Implications 
In the current study, the prior month’s CO2 as a single variable did not 
significantly correlate with albumin. When including additional continuous variable 
nutrition biomarkers with the prior month’s CO2, the selected biomarkers significantly 
correlated with albumin within-subjects (r = 0.093, p = 0.004). The results suggest the 
possibility of using a combination of biomarkers (covariates) to indicate changes in 
nutrition, which can be used in future interventions. Albumin is useful in trending nutrition, 
however should be used in combination as illustrated with other biomarkers to assess 
overall nutrition status in ESRD.  
  
Conclusion  
Low serum bicarbonate, indicating metabolic acidosis, influences nutritional 
assessment indices in hemodialysis patients. Prior month’s serum bicarbonate (~ 20 
days ago) impacts current albumin slightly more than current serum bicarbonate in a 
mixed-model ANCOVA within-subjects. Conducting this project provided further insight 
into the importance of preventing metabolic acidosis to improve nutrition biomarkers as 
well as portraying one more limitation of albumin as the main nutrition indicator in 
hemodialysis. 
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Chapter 6 
SUMMARY 
The purpose of this thesis was to: (1) determine whether serum CO2 influences 
nutrition assessment indices in hemodialysis patients; and (2) demonstrate the prior 
month’s CO2 level has a greater impact on current serum albumin versus the current 
month’s serum bicarbonate in hemodialysis patients. The sample consisted of adult in-
center hemodialysis patients at RAI in Westwood, KS.  
A limited data set with 144 patients was created by RAI. Laboratory and medical 
histories were collected for about one year. Data was collected from electronic medical 
records from December 2010 through January 2012. 
Within-subject correlations and analysis of covariance (ANCOVA) were used to 
analyze individual variables and a mixed-model to determine correlations within 
individuals. Pearson and Spearman correlations were calculated to ensure reliability of 
the within-subjects correlations for variables across subjects. Pearson and Spearman 
correlations assisted in determining the directionality (positive or negative) of the 
correlation as within-subject correlations lose negative directionality when calculating 
with a square root.   
A correlation was found between the single variables albumin and CO2 collected 
in the same month (p = 0.005) however not the prior month’s CO2 when looking at the 
individual (within-subjects) (p = 0.140). A significant Pearson correlation was found with 
albumin and the prior month’s CO2 when looking at the group as a whole (p = 0.002). 
The correlations for albumin and the prior month’s CO2 improved within-subjects when 
including additional nutritional and inflammation biomarkers in a mixed model ANCOVA. 
This suggests including additional covariates provide a better indication of overall 
nutrition status in hemodialysis patients versus only albumin when evaluating the impact 
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of metabolic acidosis.  A mixed model ANCOVA demonstrates the prior month’s serum 
CO2 level has a greater impact on current serum albumin versus the current month’s 
serum CO2 in hemodialysis patients (p = 0.004 vs. p = 0.41). 
Therefore, the prior month’s CO2 significantly correlated to albumin within-
subjects when including covariates. Results suggest the importance of considering 
additional biomarkers to indicate overall nutrition status in hemodialysis patients. Further 
intervention-based studies are needed to confirm these results. 
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APPENDIX A 
Renal Advantage Incorporated Comprehensive Patient Assessment: 
Dietitian/Nutritional Assessment 
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 Nutrition Status Criteria 
 
Malnutrition of 
Mild Degree  
Malnutrition of 
Moderate Degree  
Unspecified Severe 
Protein Calorie 
Malnutrition  
Albumin 3-3.4 g/dL <2.9 g/dL <2.5 g/dL 
Edema N/A N/A May be present 
% IBW/UBW or 
BMI 
<95% <92% <90% 
And/or BMI <17  
% Weight loss 3-5% in 1 month 
or 
5.5-7.5% in 3 
months or 
8-10% in 6 
months 
>5% in 1 month or 
>7.5% in 3 months or 
>10% in 6 months 
> 15% 
Muscle Mass N/A N/A Wasting 
Poor PO Yes Yes Possible 
Criteria needed 2 of the above 2 of the above All of the Above 
